Sana Biotechnology, Inc. (NASDAQ:SANA) Insider Fmr Llc Sells 290,912 Shares

Sana Biotechnology, Inc. (NASDAQ:SANA) insider Fmr Llc sold 290,912 shares of the firm’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the transaction, the insider now directly owns 4,541,511 shares in the company, valued at $29,474,406.39. This trade represents a 6.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Sana Biotechnology Stock Down 14.9 %

Shares of SANA stock traded down $0.64 during trading hours on Friday, reaching $3.66. 28,914,018 shares of the stock traded hands, compared to its average volume of 37,108,848. The firm has a market capitalization of $817.16 million, a PE ratio of -2.61 and a beta of 1.45. Sana Biotechnology, Inc. has a 1-year low of $1.52 and a 1-year high of $12.00. The business has a fifty day moving average price of $2.40 and a 200 day moving average price of $4.07.

Sana Biotechnology (NASDAQ:SANA) last released its earnings results on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. Research analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sana Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of SANA. Wilmington Savings Fund Society FSB purchased a new stake in shares of Sana Biotechnology in the third quarter worth approximately $29,000. Barclays PLC increased its stake in Sana Biotechnology by 126.6% in the 3rd quarter. Barclays PLC now owns 318,910 shares of the company’s stock valued at $1,325,000 after buying an additional 178,179 shares during the period. Geode Capital Management LLC lifted its position in Sana Biotechnology by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock worth $13,175,000 after buying an additional 276,055 shares in the last quarter. EP Wealth Advisors LLC acquired a new stake in shares of Sana Biotechnology during the 3rd quarter valued at $45,000. Finally, State Street Corp grew its holdings in shares of Sana Biotechnology by 4.2% during the 3rd quarter. State Street Corp now owns 6,627,320 shares of the company’s stock valued at $27,570,000 after acquiring an additional 269,274 shares in the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on SANA. HC Wainwright upped their target price on Sana Biotechnology from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday. JMP Securities lowered shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. Finally, TD Cowen upgraded shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $14.25.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.